Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Core Viewpoint - Erasca, Inc. has successfully completed a public offering of 25,875,000 shares of common stock at a price of $10.00 per share, raising approximately $258.8 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering included 3,375,000 shares sold due to the underwriters' full exercise of their option to purchase additional shares [1]. - The gross proceeds from the offering were approximately $258.8 million, which will be used for research and development, working capital, and other corporate purposes [1][2]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash and marketable securities, will fund the research and development of product candidates and other development programs [2]. Group 3: Company Overview - Erasca is a clinical-stage precision oncology company focused on therapies for patients with RAS/MAPK pathway-driven cancers, co-founded by pioneers in precision oncology [6].